Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in biotech research services, has announced the signing of four Memorandums of Understanding (MOUs) with premier clinical trial sites in Taiwan, marking a significant expansion of its Asia-Pacific operations.
The strategic partnerships have been established with Taichung Veterans General Hospital (TCVGH), Taipei Medical University (TMU), China Medical University Hospital (CMUH), and Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), reinforcing Avance Clinical's commitment to providing US biotechs with access to high-quality clinical research solutions across the region.
Avance Clinical CEO Yvonne Lungershausen emphasized the importance of these new partnerships, stating, "Expanding into Taiwan marks another key milestone for Avance Clinical as we continue to expand our global network across Asia." Lungershausen personally attended the MOU signing ceremonies to connect with the teams at these centers.
Taiwan's Clinical Research Advantages
Taiwan has emerged as an attractive destination for clinical trials due to its advanced healthcare infrastructure, highly skilled research teams, and regulatory efficiency. Joe Taouk, Vice President of Global Project Delivery at Avance Clinical, highlighted these advantages: "By partnering with these leading Taiwanese institutions, we are further strengthening our ability to support biotech sponsors in executing high-quality, efficient clinical trials with access to diverse patient populations."
Kelly Yang, Associate Director of Taiwan Operations, added that these partnerships will provide biotech sponsors with streamlined access to Taiwan's high-quality clinical trial ecosystem, enabling clients to accelerate therapy development while maintaining the highest scientific and ethical standards.
Partner Institutions' Specialized Capabilities
Each partner institution brings unique strengths to the collaboration. Taichung Veterans General Hospital has established itself as a leader in advanced CAR-T cell immunotherapy, ranking second in Taiwan for the number of treated cases and achieving a 100% cure rate.
Professor Yun-Ching Fu, Dean of TCVGH, expressed optimism about the partnership: "This collaboration will accelerate the development of cancer treatments and other groundbreaking therapies, bringing life-changing benefits to patients worldwide."
Taipei Medical University's Executive Vice President, Professor Chun-Che Shih, emphasized the global impact of the partnership: "This collaboration enhances our medical centers' ability to make a significant impact, strengthens our presence in global trials, and ultimately improves healthcare through innovation."
Expanding Research Opportunities
The partnerships also create new opportunities for early-phase studies and international research. Professor Der-Yang Cho, Dean of China Medical University Hospital, noted: "We are excited to collaborate with Avance Clinical to expand international research opportunities and further strengthen our capabilities in early-phase studies. This agreement not only enhances our ability to support global biotech companies but also accelerates the delivery of innovative treatments to patients."
Jaw-Yuan Wang, Superintendent of Kaohsiung Medical University Chung-Ho Memorial Hospital, highlighted the benefits for patients: "By combining our clinical research expertise and diverse patient population with Avance Clinical's global trial management capabilities, we can accelerate the development of new therapies and provide our patients with earlier access to groundbreaking treatments."
Strengthening the GlobalReady Model
These agreements reinforce Avance Clinical's GlobalReady model, which offers biotech companies a seamless pathway to leverage the region's clinical trial capabilities, regulatory efficiencies, and patient access. With 30 years of experience and expertise spanning over 250 indications, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs.
The expansion into Taiwan represents a strategic enhancement of Avance Clinical's services, providing biotechnology companies with additional options for conducting high-quality clinical trials in a region known for its medical excellence and research capabilities.
For US biotech companies looking to accelerate their clinical development programs, these new partnerships offer an opportunity to tap into Taiwan's advanced healthcare ecosystem while benefiting from Avance Clinical's comprehensive trial management expertise.
